As of May 22, 2025, Vericel Corp (VCEL) reports a Forward P/E of 164.35.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Vericel Corp's Forward P/E to Peers
To better understand Vericel Corp's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Vericel Corp (VCEL) | 164.35 |
| BioCryst Pharmaceuticals Inc (BCRX) | 328.73 |
| Organogenesis Holdings Inc (ORGO) | 79.47 |
| MiMedx Group Inc (MDXG) | 27.50 |
| Vertex Pharmaceuticals Inc (VRTX) | 23.83 |
| MannKind Corp (MNKD) | 22.71 |
Compared to its competitors, Vericel Corp's Forward P/E is among the highest compared to peers, reflecting higher growth expectations from investors.